Download PDF
Thromb Haemost 1991; 66(05): 520-524
DOI: 10.1055/s-0038-1646452
Original Article
Schattauer GmbH Stuttgart

The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study

A A Long
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
J S Ginsberg
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
P Brill-Edwards
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
M Johnston
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
C Turner
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
J A Denburg
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
W G Bensen
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
A Cividino
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
M Andrew
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
,
J Hirsh
The Departments of Medicine and Pediatrics, McMaster University, Hamilton, Canada
› Author Affiliations
Further Information

Publication History

Received 06 July 1990

Accepted 24 April 1991

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In order to determine whether an association exists between antiphospholipid antibodies (APLA) and thromboembolic events in patients with systemic lupus erythematosus (SLE), we performed a cross-sectional study of consecutive unselected SLE patients. The occurrence of previous thromboembolic events was determined by investigators blinded to the APLA status of the patients by critical review of objective tests that had been performed at the time of symptomatic presentation and by performing venous Doppler ultrasound of the legs to elicit venous reflux as an indication of previous venous thrombosis. The presence of APLA was determined by coagulation assays for the lupus anticoagulant (LA) using five tests with well-defined control ranges and by ELISA assay for anticardiolipin antibodies (ACLA). These tests were measured on two separate occasions. The results of the study demonstrate a statistically significant association between persistently abnormal ACLA assays and thromboembolic events and a non-significant trend between persistently abnormal LA and thromboembolic events. Transient abnormalities of LA and ACLA were less strongly associated with thromboembolic events. We conclude that in patients with SLE, there is a significant association between thromboembolism and APLA.

 

  • References

  • 1 Conley CL, Hartman RC. A haemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-2
    PubMedGoogle Scholar
  • 2 Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76
    PubMedGoogle Scholar
  • 3 Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30
    PubMedGoogle Scholar
  • 4 Mueh JR, Herbst KD, Rappaport SI. Thrombosis in patients with lupus anticoagulant. Ann Intern Med 1980; 92: 156-9
    CrossrefPubMedGoogle Scholar
  • 5 Elias M, Eldor A. Thromboembolism in patients with the "lupus-type" circulating anticoagulant. Arch Intern Med 1984; 144: 510-5
    CrossrefPubMedGoogle Scholar
  • 6 Manoharan A, Gibson L, Rush B, Feery BS. Recurrent venous thrombosis with a lupus coagulation inhibitor in the absence of systemic lupus. Aust NZ J Med 1977; 7: 422-6
    CrossrefPubMedGoogle Scholar
  • 7 Angles-Cano G, Sultan Y, Calurel J. Predisposing factors to thrombosis in SLE. J Lab Clin Med 1979; 94: 312-23
    PubMedGoogle Scholar
  • 8 Boey MC, Calaco CB, Chavari AE. et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-3
    CrossrefPubMedGoogle Scholar
  • 9 Glueck HI, Kant KS, Weiss MA, Pollak VE, Miller MA, Coots M. Thrombosis and systemic lupus erythematosus: relation to the presence of circulating anticoagulants. Arch Intern Med 1985; 145: 1389-95
    CrossrefPubMedGoogle Scholar
  • 10 Liote F, Mannedouche T, Meyer O, Dautenberg MD, Jungers P. Recurrent thrombosis and lupus anticoagulant in systemic lupus erythematosus. Arch Intern Med 1986; 146: 1247
    PubMedGoogle Scholar
  • 11 Pauzner R, Rosner E, Many A. Circulating anticoagulant in systemic lupus erythematosus: Clinical manifestations. Acta Haematol 1986; 76: 90-4
    CrossrefPubMedGoogle Scholar
  • 12 Derksen RH, Bouma BN, Kater L. The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol 1987; 16: 185-92
    CrossrefPubMedGoogle Scholar
  • 13 Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellman D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom and anticardiolipin antibody level. Ann Intern Med 1987; 106: 524-31
    CrossrefPubMedGoogle Scholar
  • 14 Harris EN, Boey ML, Mackworth-Young CG. et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4
    PubMedGoogle Scholar
  • 15 Lechner K, Pazbwinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 1985; 15: 254-62
    PubMedGoogle Scholar
  • 16 Sturfelt G, Nived O, Norberg R, Thorstensson R, Krook K. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 382-8
    CrossrefPubMedGoogle Scholar
  • 17 Wheeler HB, Anderson Jr FA. Diagnostic approaches for deep vein thrombosis. Chest 1986; 89 (5) 4075-125
    PubMedGoogle Scholar
  • 18 Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 257-70
    PubMedGoogle Scholar
  • 19 Huisman M, Buller HR, ten Cate JW. Unexpected high prevalence of silent pulmonary embolism in patients with deep vein thrombosis. Chest 1989; 95: 498-502
    CrossrefPubMedGoogle Scholar
  • 20 Green D, Hougie C, Kazmier FJ. et al. Report of the working part on acquired inhibitors of coagulation: studies of the "lupus" anticoagulant. Thromb Haemostas 1983; 49: 144-6
    PubMedGoogle Scholar
  • 21 Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time - the central role of phosphatidyl serine. Thromb Haemostas 1984; 52: 172-5
    PubMedGoogle Scholar
  • 22 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-74
    PubMedGoogle Scholar
  • 23 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-51
    CrossrefPubMedGoogle Scholar
  • 24 Kalunian KC, Peter JB, Middlekauff HR. et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85 (5) 602-8
    CrossrefPubMedGoogle Scholar
  • 25 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
    CrossrefPubMedGoogle Scholar
  • 26 Linder DJ, Edwards JM, Phinney ES. et al. Long term haemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986; 4: 436-42
    CrossrefPubMedGoogle Scholar
  • 27 Ginsberg JS, Shin A, Turpie AGG, Hirsh J. Detection of previous proximal venous thrombosis with doppler ultrasonography and photoplethysmography. Arch Intern Med 1989; 149: 2255-7
    CrossrefPubMedGoogle Scholar
  • 28 Johnston M, Carter CJ. The use of diagnostic algorithms for APTT inhibitors. IX. International Congress on Thrombosis and Haemostasis. Thromb Haemostas 1983; 50: 270 (Abstr)
    PubMedGoogle Scholar
  • 29 Bell WN, Alton HG. A brain extract as a substitute for platelet suspension in the thromboplastin generation test. Nature 1954; 174: 880-1
    CrossrefPubMedGoogle Scholar
  • 30 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-9
    CrossrefPubMedGoogle Scholar
  • 31 Thiagarajan P, Shapiro SS, DeMarco L. Monoclonal immunoglobulin Mλ coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
    CrossrefPubMedGoogle Scholar
  • 32 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48 (4) 499-509
    PubMedGoogle Scholar
  • 33 Loizou S, McRea DJ, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45
    PubMedGoogle Scholar